The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Olpadronate     (3-dimethylamino-1-hydroxy-1- phosphono...

Synonyms: Me2-APD, CHEMBL55812, LS-186873, LS-187528, FT-0673282, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Me2-APD


High impact information on Me2-APD


Chemical compound and disease context of Me2-APD


Biological context of Me2-APD


Anatomical context of Me2-APD


Analytical, diagnostic and therapeutic context of Me2-APD

  • We showed that 3,3-dimethylaminopropane-1-hydroxy-1,1-diphosphonic acid (olpadronate) was the most effective bisphosphonate treatment in reducing tumor burden as assessed by GFP imaging and radiography [3].
  • We addressed these issues in a longitudinal study of 157 patients with biochemically active disease (serum alkaline phosphatase activity >120 U/L) treated with the bisphosphonate olpadronate and followed for a median period of 37 months (range 3-162, mean 46 +/- 30) [15].
  • We treated three boys with severe OI type III and vertebral deformities for 5-7 years with continuous oral administration of the bisphosphonate, olpadronate [16].
  • Effect of topical administration of monosodium olpadronate on experimental periodontitis in rats [17].
  • None of the patients treated with local radiotherapy, only 4% of patients receiving 89Sr and 21% of patients given olpadronate developed this complication [9].


  1. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. van der Pluijm, G., Vloedgraven, H., van Beek, E., van der Wee-Pals, L., Löwik, C., Papapoulos, S. J. Clin. Invest. (1996) [Pubmed]
  2. Short-term therapy with oral olpadronate in active Paget's disease of bone. González, D.C., Mautalen, C.A. J. Bone Miner. Res. (1999) [Pubmed]
  3. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model. Yang, M., Burton, D.W., Geller, J., Hillegonds, D.J., Hastings, R.H., Deftos, L.J., Hoffman, R.M. Clin. Cancer Res. (2006) [Pubmed]
  4. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Pelger, R.C., Hamdy, N.A., Zwinderman, A.H., Lycklama à Nijeholt, A.A., Papapoulos, S.E. Bone (1998) [Pubmed]
  5. Modulation of cytosolic calcium levels in osteoblast-like osteosarcoma cells by olpadronate and its amino-derivative IG-9402. Vazquez, G., Santillan, G., Boland, R., Roldán, E., Pérez-Lloret, A. Calcif. Tissue Int. (2003) [Pubmed]
  6. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. Plotkin, L.I., Weinstein, R.S., Parfitt, A.M., Roberson, P.K., Manolagas, S.C., Bellido, T. J. Clin. Invest. (1999) [Pubmed]
  7. Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone. Cremers, S.C., Eekhoff, M.E., Den Hartigh, J., Hamdy, N.A., Vermeij, P., Papapoulos, S.E. J. Bone Miner. Res. (2003) [Pubmed]
  8. Differential effects of aminosubstituted analogs of hydroxy bisphosphonates on the growth of Dictyostelium discoideum. Brown, R.J., van Beek, E., Watts, D.J., Löwik, C.W., Papapoulos, S.E. J. Bone Miner. Res. (1998) [Pubmed]
  9. Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. Soerdjbalie-Maikoe, V., Pelger, R.C., Lycklama à Nijeholt, G.A., Arndt, J.W., Zwinderman, A.H., Papapoulos, S.E., Hamdy, N.A. Eur. J. Nucl. Med. Mol. Imaging (2002) [Pubmed]
  10. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Van Beek, E.R., Löwik, C.W., Papapoulos, S.E. Bone (2002) [Pubmed]
  11. Olpadronate reduced fractures in children with osteogenesis imperfecta. Cole, W.G. The Journal of bone and joint surgery. American volume. (2004) [Pubmed]
  12. Serum kinetics, bioavailability and bone scanning of 99mTc-labelled sodium olpadronate in patients with different rates of bone turnover. Degrossi, O.J., Ortiz, M., Degrossi, E.B., García del Río, H., Barreira, J.C., Messina, D., Kerzberg, E., Roldán, E.J., Montuori, E., Pérez Lloret, A. Eur. J. Clin. Pharmacol. (1995) [Pubmed]
  13. Olpadronate: a new amino-bisphosphonate for the treatment of medical osteopathies. Roldán, E.J., Pérez-Llore, A., Ferretti, J.L. Expert opinion on investigational drugs. (1998) [Pubmed]
  14. Intravenous olpadronate restores ovariectomy-affected bone strength. A mechanical, densitometric and tomographic (pQCT) study. Cointry, G.R., Mondelo, N., Zanchetta, J.R., Montuori, E., Ferretti, J.L. Bone (1995) [Pubmed]
  15. Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy. Eekhoff, M.E., Zwinderman, A.H., Haverkort, D.M., Cremers, S.C., Hamdy, N.A., Papapoulos, S.E. Bone (2003) [Pubmed]
  16. Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate). Landsmeer-Beker, E.A., Massa, G.G., Maaswinkel-Mooy, P.D., van de Kamp, J.J., Papapoulos, S.E. Eur. J. Pediatr. (1997) [Pubmed]
  17. Effect of topical administration of monosodium olpadronate on experimental periodontitis in rats. Goya, J.A., Paez, H.A., Mandalunis, P.M. J. Periodontol. (2006) [Pubmed]
WikiGenes - Universities